Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-BCMA CAR-T for Relapsed/Refractory Multiple Myeloma
NCT03943472Phase 1Unknown
- Sponsor
- Shanghai HRAIN Biotechnology
- Start
- Jul 2019
- Primary completion
- Nov 2021
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of anti-BCMA CAR-T cells in multiple myeloma (MM) (2 arms), sponsored by Shanghai HRAIN Biotechnology. Primary endpoint: Occurrence of study related adverse effects defined by NCI CTCAE 5.0 at 6 months. Status: unknown.
02
Drugs
anti-BCMA CAR-T cells
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03943472.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03943472.